TELAGARA is a modern fixed-dose combination antiretroviral therapy (ART) containing three active agents with complementary mechanisms of action.
How it works:
Dolutegravir inhibits HIV integrase, preventing integration of viral DNA into the host genome. Tenofovir alafenamide and emtricitabine inhibit reverse transcriptase, blocking viral replication. The combined effect results in rapid and sustained reduction of viral load.
Recommended for:
Clinical evidence:
Dolutegravir-based regimens demonstrate high efficacy and a strong resistance barrier. Clinical trials show rapid viral load reduction and high rates of undetectable HIV RNA levels. Tenofovir alafenamide offers improved renal and bone safety compared to tenofovir disoproxil formulations. Long-term studies confirm durable virologic suppression and favorable tolerability.
Indicated for the treatment of HIV-1 infection in adults and adolescents as prescribed by a healthcare provider. The goal of therapy is to suppress viral replication, achieve undetectable viral load, and preserve immune function.
Take orally once daily or as directed by a physician. The tablet should be taken consistently at the same time each day. Treatment is long-term and requires regular monitoring of viral load and immune parameters.
Contraindications
Side Effects
